<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368093</url>
  </required_header>
  <id_info>
    <org_study_id>C09060-1</org_study_id>
    <nct_id>NCT02368093</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TSH Biopharm Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis were randomized to a 6-month treatment of oral dextromethorphan
      hydrobromide or placebo as an add-on therapy to traditional disease-modifying anti-rheumatic
      drugs (DMARDs). Disease activity were assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologic-naïve rheumatoid arthritis (RA) patients who fulfilled the 2010 criteria of the
      American College of Rheumatology (ACR) for RA were enrolled. All patient were randomized to
      a 6-month treatment with either oral DXM [dextromethorphan hydrobromide; Detosiv Slow
      Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan) with T1/2 = 7.75h,
      Tmax = 4.83h, Cmax = 14.6 ng mL-1 and mean residual time = 5.86 h, 120mg per day with once
      daily dose taken after breakfast] or placebo pills with the same appearance as DXM tablets.
      The randomization was performed by the pharmacy of the Taichung Veterans General Hospital.
      Non-study medications were not changed during the course of study.

      Twenty-four patients received add-one DXM therapy and the other 24 patients received
      traditional DMARDs alone in stable dose. Disease activity was assessed by the 28-joint
      disease activity score (DAS28) before starting add-on DXM therapy (as a baseline) and at the
      end of 6 months of therapy with or without add-on DXM. Patients were categorized as good,
      moderate or poor responders based on the amount of change in the DAS28 and the level of
      DAS28 reached. Good responders were defined as patients who had a decrease in DAS28 from
      baseline (∆DAS28)＞1.2 and a DAS28≦3.2 at evaluation time; moderate responders had either
      ∆DAS28＞1.2 and a DAS28&gt;3.2 or ∆DAS28 of 0.6-1.2 and a DAS28≦5.1 at evaluation time; and poor
      responders were those who had either ∆DAS28＜0.6 or a DAS28&gt;5.1 at evaluation time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Good European League Against Rheumatism (EULAR) Therapeutic Response Rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Dextromethorphan hydrobromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pills with the same appearance as Detosiv tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan hydrobromide</intervention_name>
    <description>120mg per day with once daily dose taken after breakfast for 6 months</description>
    <arm_group_label>Dextromethorphan hydrobromide</arm_group_label>
    <other_name>Detosiv Slow Release®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the 2010 criteria of the American College of Rheumatology (ACR)
             for RA

        Exclusion Criteria:

          -  Receive biological therapy for RA, including Etanercept, Adalimumab, Golimumab,
             Tocilizumab, Rituximab, Abatacept.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Der-Yuan Chen, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Allergy,Immunology and Rheumatology, Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 22, 2015</lastchanged_date>
  <firstreceived_date>February 4, 2015</firstreceived_date>
  <firstreceived_results_date>March 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dextromethorphan</title>
          <description>Biologic-naïve rheumatoid arthritis patients who fulfilled the 2010 criteria of the American College of Rheumatology for RA were enrolled.
Dextromethorphan hydrobromide 120mg once daily were given for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Biologic-naïve rheumatoid arthritis patients who fulfilled the 2010 criteria of the American College of Rheumatology for RA were enrolled.
Placebo pills with the same appearance as Dextromethorphan hydrobromide tablets once daily were given for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dextromethorphan Hydrobromide</title>
          <description>Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo pills with the same appearance as Detosiv tablets once daily for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52.2" spread="11.6"/>
                <measurement group_id="B2" value="52.8" spread="10.5"/>
                <measurement group_id="B3" value="52.5" spread="11.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Ethnicity of participants</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Taiwan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Good European League Against Rheumatism (EULAR) Therapeutic Response Rate</title>
        <time_frame>6 months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dextromethorphan Hydrobromide</title>
            <description>Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
Dextromethorphan hydrobromide: 120mg per day with once daily dose taken after breakfast for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pills with the same appearance as Detosiv tablets.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Good European League Against Rheumatism (EULAR) Therapeutic Response Rate</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dextromethorphan</title>
          <description>Biologic-naïve rheumatoid arthritis patients who fulfilled the 2010 criteria of the American College of Rheumatology for RA were enrolled.
Dextromethorphan hydrobromide 120mg once daily were given for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Biologic-naïve rheumatoid arthritis patients who fulfilled the 2010 criteria of the American College of Rheumatology for RA were enrolled.
Placebo pills with the same appearance as Dextromethorphan hydrobromide tablets once daily were given for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Der-Yuan Chen</name_or_title>
      <organization>Taichung Veterans General Hospital</organization>
      <phone>884-4-23592525 ext 3354</phone>
      <email>dychen@vghtc.gov.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
